Skip to content
Cytarabine, Depocyte(cytarabine)
Cytosar-u, DepoCyte, Depocyt, Vyxeos (cytarabine) is a small molecule pharmaceutical. Cytarabine was first approved as Cytarabine on 1982-01-01. It is used to treat leukemia, lymphoma, and meningeal neoplasms in the USA. It has been approved in Europe to treat meningeal neoplasms and myeloid leukemia acute.
Download report
Favorite
Drugs Approved for Childhood Cancers
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
nervous system diseasesD009422
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Combinations
Vyxeos
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cytarabine
Tradename
Company
Number
Date
Products
DEPOCYTPacira BioSciencesN-021041 DISCN1999-04-01
1 products, RLD
CYTARABINETevaN-016793 DISCN1982-01-01
4 products, RLD
Hide discontinued
Cytarabine
+
Daunorubicin
Tradename
Company
Number
Date
Products
VYXEOSCelator PharmaceuticalsN-209401 RX2017-08-03
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
cytarabineANDA2023-05-31
vyxeosNew Drug Application2021-04-13
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
leukemiaD007938C95
lymphomaD008223C85.9
meningeal neoplasmsEFO_0003851D008577C70
Agency Specific
FDA
EMA
Expiration
Code
CYTARABINE / DAUNORUBICIN, VYXEOS, CELATOR PHARMS
2028-03-30ODE-350
2024-08-03ODE-287
2024-03-30NPP
Patent Expiration
Patent
Expires
Flag
FDA Information
Cytarabine / Daunorubicin, Vyxeos, Celator Pharms
100289122032-10-15DPU-3149, U-3150
101661842032-10-15DPU-3149
108354922032-10-15U-3150
80928282029-04-01U-3147
80222792027-09-14DPU-3147
78509902027-01-23DPU-3147
92719312027-01-23DP
85184372026-06-07DP
84318062025-04-22DPU-3147
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01B: Antimetabolites
L01BC: Pyrimidine analogues, antineoplastic antimetabolites
L01BC01: Cytarabine
L01X: Other antineoplastic agents in atc
L01XY: Combinations of antineoplastic agents
L01XY01: Cytarabine and daunorubicin
HCPCS
Code
Description
J9098
Injection, cytarabine liposome, 10 mg
J9100
Injection, cytarabine, 100 mg
J9153
Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine
Clinical
Clinical Trials
1112 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.0187232741114438
LeukemiaD007938C95571186329220
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.0498837188175
Myelodysplastic syndromesD009190D4658891716140
Non-hodgkin lymphomaD008228C85.9153221546
Large b-cell lymphoma diffuseD016403C83.382351133
Mantle-cell lymphomaD020522C83.182321129
Burkitt lymphomaD002051C83.76132117
Promyelocytic leukemia acuteD015473C92.4425313
Hematologic neoplasmsD0193374317
Show 3 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223C85.917802610129
Myeloid leukemiaD007951C9217167238
Monocytic leukemia acuteD00794815156235
Myelomonocytic leukemia acuteD015479C92.515145234
Erythroblastic leukemia acuteD004915EFO_1001257C94.015125232
Megakaryoblastic leukemia acuteD007947C94.214125231
Hodgkin diseaseD006689C818134424
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340913221
Myelomonocytic leukemia chronicD015477C93.11081218
Philadelphia chromosomeD01067739212
Show 18 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Biphenotypic leukemia acuteD015456C95.0810115
Plasma cell neoplasmsD0542192619
NeoplasmsD009369C805418
Follicular lymphomaD008224C824718
B-cell lymphomaD016393437
B-cell chronic lymphocytic leukemiaD015451C91.11516
Myeloproliferative disordersD009196D47.12416
Precursor t-cell lymphoblastic leukemia-lymphomaD054218425
Primary myelofibrosisD055728D47.4324
Myeloid leukemia chronic-phaseD01546644
Show 48 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia accelerated phaseD01546544
HypersensitivityD006967EFO_0003785T78.4011
SyndromeD01357711
Leukemia myeloid chronic atypical bcr-abl negativeD054438C92.211
Neutrophilic leukemia chronicD015467D47.111
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Sickle cell anemiaD000755EFO_0000697D5711
Hemoglobin sc diseaseD006450EFO_1001797D57.211
Extranodal nk-t-cell lymphomaD054391C86.011
B-cell lymphoma marginal zoneD018442C88.411
Adult t-cell leukemia-lymphomaD015459C91.511
Hairy cell leukemiaD007943C91.411
Intraocular lymphomaD06409011
Large granular lymphocytic leukemiaD05406611
Large-cell lymphoma immunoblasticD01640011
Lymphomatoid granulomatosisD008230C83.811
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCYTARABINE
INNcytarabine
Description
Cytarabine is a pyrimidine nucleoside in which cytosine is attached to D-arabinofuranose via a beta-N(1)-glycosidic bond. Used mainly in the treatment of leukaemia, especially acute non-lymphoblastic leukaemia, cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. It also has antiviral and immunosuppressant properties. It has a role as an antineoplastic agent, an antimetabolite, an antiviral agent and an immunosuppressive agent. It is a beta-D-arabinoside, a pyrimidine nucleoside and a monosaccharide derivative. It is functionally related to a cytosine.
Classification
Small molecule
Drug classantineoplastics (arabinofuranosyl derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Identifiers
PDB
CAS-ID147-94-4
RxCUI3041
ChEMBL IDCHEMBL803
ChEBI ID28680
PubChem CID6253
DrugBankDB00987
UNII ID04079A1RDZ (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Depocyte - Pacira BioSciences
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Vyxeos - Jazz Pharmaceuticals
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 25,743 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cytarabine, Vyxeos
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,329 adverse events reported
View more details